Citadel Advisors
SVA

Citadel Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Citadel Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-34,193
Closed -$256K – 8892
2017
Q3 		$241K Buy
+34,193
New +$233K ﹤0.01% 6408
2016
Q4 		– Sell
-13,084
Closed -$77K – 8461
2016
Q3 		$77K Buy
+13,084
New +$77K ﹤0.01% 6738
2015
Q2 		– Sell
-108,652
Closed -$539K – 9558
2015
Q1 		$539K Sell
108,652
-47,585
-30% -$234K ﹤0.01% 4786
2014
Q4 		$817K Sell
156,237
-801
-0.5% -$4.08K ﹤0.01% 4021
2014
Q3 		$755K Sell
157,038
-12,724
-7% -$68.3K ﹤0.01% 4073
2014
Q2 		$958K Buy
169,762
+41,185
+32% +$250K ﹤0.01% 3553
2014
Q1 		$926K Buy
128,577
+117,557
+1,067% +$778K ﹤0.01% 3520
2013
Q4 		$67K Sell
11,020
-12,840
-54% -$77.4K ﹤0.01% 5887
2013
Q3 		$143K Buy
23,860
+1,534
+7% +$7.33K ﹤0.01% 5061
2013
Q2 		$88K Buy
+22,326
New +$83.1K ﹤0.01% 5312

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSP
Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's SVA Position: Q4 2017 in Review

Citadel Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q4 2017, closing a stake of 34,193 shares — an estimated $256K sold.

Citadel Advisors first reported a position in SVA in Q2 2013 and held it in 10 quarters. The position peaked at $958K in Q2 2014. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

  • Citadel Advisors reported no remaining Sinovac Biotech, Ltd position as of Q4 2017 after selling out during the quarter.
  • Citadel Advisors sold 34,193 Sinovac Biotech, Ltd shares in Q4 2017, an estimated $256K.
  • Citadel Advisors first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 10 quarters.
  • Citadel Advisors's Sinovac Biotech, Ltd position peaked at $958K in Q2 2014.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2017.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.